Anastasia Voevodin

Anastasia Voevodin, PhD, is an Analyst in Public Equity at Sofinnova Investments, based in New York, NY. She joined Sofinnova BioEquities in 2024 and is primarily focused on public biotech investments, leveraging her scientific expertise to identify and evaluate opportunities in the biotechnology sector. Her role centers on sourcing, analyzing, and recommending investments in publicly traded biotechnology companies, utilizing deep sector research and financial analysis.

Prior to joining Sofinnova, Anastasia was a Senior Associate in Investment Analysis at Avoro Capital Advisors (formerly venBio Select Advisor), where she covered life sciences and biopharmaceuticals, contributing to investment decisions and portfolio strategies from 2022 to 2024. She also has prior consulting experience in Strategy Insights and Planning at ZS, supporting healthcare and pharmaceutical clients with strategic projects.

Anastasia holds a Ph.D. in Chemistry from Columbia University and a Bachelor of Arts in Chemistry from Boston University. Her interdisciplinary background in science and finance enhances her ability to assess investment prospects in biotechnology and pharma, and she is recognized for her rigorous analytical skills and sector knowledge within public equities.